^
Association details:
| Biomarker: | TP53 deletion |
|---|---|
| Cancer: | Lymphoma |
| Drug: | Alunbrig (brigatinib) (EGFR inhibitor, ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib
Published date:
06/25/2023
Excerpt:
We established a patient-derived xenograft (PDX) resource from ALK+ ALCL patients at or before CNS relapse serving as models to facilitate the development of future therapies. We show in vivo that brigatinib is effective in inducing the remission of PDX models of crizotinib-resistant (ALK C1156Y, TP53 loss) ALCL and furthermore that it is superior to crizotinib as a second-line approach to the treatment of a standard chemotherapy relapsed/refractory ALCL PDX pointing to brigatinib as a future therapeutic option.
DOI:
10.1111/bjh.18953
